


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

5

1. (Original) A compound according to the general Formula (I)



10 the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the N-oxide form thereof and prodrugs thereof, wherein :

n is an integer, equal to 0, 1 or 2;

15 m is an integer, equal to 1 or 2, provided that if m is 2, then n is 1;

p is an integer equal to 1 or 2;

q is an integer equal to 0 or 1;

Q is O or NR<sup>3</sup>;

20 X is a covalent bond or a bivalent radical of formula - O-, -S- or -NR<sup>3</sup>-;

each R<sup>3</sup> independently from each other, is hydrogen or alkyl;

each R<sup>1</sup> independently from each other, is selected from the group of Ar<sup>1</sup>, Ar<sup>1</sup>-alkyl and di(Ar<sup>1</sup>)-alkyl;

25 R<sup>2</sup> is Ar<sup>2</sup>, Ar<sup>2</sup>-alkyl, di(Ar<sup>2</sup>)alkyl, Het<sup>1</sup> or Het<sup>1</sup>-alkyl;

Y is a covalent bond or a bivalent radical of formula - C(=O)-, -SO<sub>2</sub>- >C=CH-R or >C=N-R, wherein R is H, CN or nitro ;

30 each Alk represents, independently from each other, a covalent bond; a bivalent straight or branched, saturated or unsaturated hydrocarbon radical

having from 1 to 6 carbon atoms; or a cyclic saturated or unsaturated hydrocarbon radical having from 3 to 6 carbon atoms; each radical optionally substituted on one or more carbon atoms with one or more alkyl, phenyl, halo, cyano, hydroxy, formyl and amino radicals;

5                   L       is selected from the group of hydrogen, alkyl, alkyloxy, Ar<sup>3</sup>-oxy, alkyloxycarbonyl, mono- and di(alkyl)amino, mono- and di(Ar<sup>3</sup>)amino, Ar<sup>3</sup>, Ar<sup>3</sup>carbonyl, Het<sup>2</sup> and Het<sup>2</sup>carbonyl;

10                   Ar<sup>1</sup> is phenyl, optionally substituted with 1, 2 or 3 substituents, each independently from each other, selected from the group of halo, alkyl, cyano, aminocarbonyl and alkyloxy;

15                   Ar<sup>2</sup> is naphthalenyl or phenyl, each optionally substituted with 1, 2 or 3 substituents, each independently from each other, selected from the group of halo, nitro, amino, mono- and di(alkyl)amino, cyano, alkyl, hydroxy, alkyloxy, carboxyl, alkyloxycarbonyl, aminocarbonyl and mono- and di(alkyl)aminocarbonyl;

20                   Ar<sup>3</sup> is naphthalenyl or phenyl, optionally substituted with 1, 2 or 3 substituents, each independently from each other, selected from the group of alkyloxy, alkyl, halo, hydroxy, pyridinyl, morpholinyl, pyrrolidinyl, imidazo[1,2-a]pyridinyl, morpholinylcarbonyl, pyrrolidinylcarbonyl, amino and cyano;

25                   Het<sup>1</sup> is a monocyclic heterocyclic radical selected from the the group of pyrrolyl, pyrazolyl, imidazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl and pyridazinyl; or a bicyclic heterocyclic radical

30                   selected from the group of quinolinyl, quinoxalinyl, indolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl,

35

benzothiazolyl, benzofuranyl and benzothienyl;  
each heterocyclic radical may optionally be  
substituted on any atom by a radical selected  
from the group of halo and alkyl;

5        Het<sup>2</sup> is a monocyclic heterocyclic radical  
selected from the group of pyrrolidinyl,  
dioxolyl, imidazolidinyl, pyrrazolidinyl,  
piperidinyl, morpholinyl, dithianyl,  
thiomorpholinyl, piperazinyl, imidazolidinyl,  
10        tetrahydrofuranyl, 2H-pyrrolyl, pyrrolinyl,  
imidazolinyl, pyrrazolinyl, pyrrolyl, imidazolyl,  
pyrazolyl, triazolyl, furanyl, thienyl, oxazolyl,  
isoxazolyl, thiazolyl, thiadiazolyl,  
isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl,  
15        pyridazinyl and triazinyl;

or a bicyclic heterocyclic radical selected  
from the group of benzopiperidinyl, quinolinyl,  
quinoxalinyl, indolyl, isoindolyl, chromenyl,  
benzimidazolyl, imidazo[1,2-a]pyridinyl,  
20        benzoxazolyl, benzisoxazolyl, benzothiazolyl,  
benzothiazolyl, benzofuranyl and benzothienyl;

each radical optionally substituted with one  
or more radicals selected from the group of Ar<sup>1</sup>,  
Ar<sup>1</sup>alkyl, halo, hydroxy, alkyl, piperidinyl,  
25        pyrrolyl, thienyl, oxo, alkyloxy, alkyloxyalkyl  
and alkyloxycarbonyl; and

alkyl is a straight or branched saturated hydrocarbon  
radical having from 1 to 6 carbon atoms or a  
cyclic saturated hydrocarbon radicals having from  
30        3 to 6 carbon atoms; optionally substituted on one  
or more carbon atoms with one or more radicals  
selected from the group of phenyl, halo, cyano,  
oxo, hydroxy, formyl and amino.

35    2.    (Original) A compound according to claim 1,  
characterized in that

n    is 1;

- m is 1;  
p is 1;  
q is 0;  
Q is 0;  
5 X is a covalent bond;  
each R<sup>1</sup> is Ar<sup>1</sup> or Ar<sup>1</sup>-alkyl;  
  
R<sup>2</sup> is Ar<sup>2</sup>;  
Y is a covalent bond or a bivalent radical of formula -  
10 C(=O) - ;  
each Alk represents, independently from each other, a  
covalent bond  
L is selected from the group of hydrogen, alkyloxy, Ar<sup>3</sup>  
and Het<sup>2</sup>;  
15 Ar<sup>1</sup> is phenyl;  
Ar<sup>2</sup> is phenyl, optionally substituted with 1, 2 or 3 alkyl  
radicals;  
Ar<sup>3</sup> is phenyl, optionally substituted with 1, 2 or 3  
substituents, each independently from each other,  
20 selected from the group of alkyl and halo;  
Het<sup>2</sup> is a monocyclic heterocyclic radical selected from  
the group of pyrazolyl, furanyl and isoxazolyl,  
each radical optionally substituted with one or  
more alkyl radicals; and  
25 alkyl is a straight hydrocarbon radical having 1 to 6  
carbon atoms, optionally substituted with one or  
more halo radicals.
3. (Currently Amended) A compound according to Claim 1  
30 ~~any of claims 1-2, characterized in that~~ wherein R<sup>1</sup> is  
Ar<sup>1</sup>methyl and attached to the 2-position or R<sup>1</sup> is Ar<sup>1</sup> and  
attached to the 3-position.
4. (Currently Amended) A compound according to ~~any of~~  
35 ~~claims 1-3, characterized in that~~ Claim 1 wherein the  
R<sup>2</sup>-X-C(=Q)- moiety is 3,5-di-(trifluoromethyl)  
phenylcarbonyl.

5. (Currently Amended) A compound according to ~~any of~~  
~~claims 1-4, characterized in that~~ Claim 1 wherein p is  
1.
- 5
6. (Currently Amended) A compound according to ~~any of~~  
~~claims 1-5, characterized in that~~ Claim 1 wherein Y is -  
C(=O) - .
- 10 7. (Currently Amended) A compound according to ~~any of~~  
~~claims 1-6, characterized in that~~ Claim 1 wherein Alk is  
a covalent bond.
8. (Currently Amended) A compound according to ~~any of~~  
15 ~~claims 1-3, characterized in that~~ Claim 1 wherein L is  
Het<sup>2</sup>.
9. (Canceled)
- 20 ~~11- 10.~~ (Currently Amended) A compound according to ~~any~~  
~~one of claims 1-10~~ claim 1 for use as an orally  
active, ~~central penetrating~~ medicine.
- 25 ~~12- 11.~~ (Currently Amended) ~~The use of a compound according~~  
~~to any one of claims 11 for the manufacture of a~~  
medicament for treating A method for the treatment  
and/or prophylaxis of tachykinin mediated conditions  
comprising administering to a human in need of such  
administration of an effective amount of a compound  
30 according to claim 1.
- 35 ~~13- 12.~~ (Currently Amended) ~~The use of a compound according~~  
~~to claim 1-11 for the manufacture of a medicament for~~  
~~treating~~ A method for the treatment and/or prophylaxis  
of schizophrenia, emesis, anxiety, depression,  
irritable bowel syndrome (IBS), circadian rhythm  
disturbances, pain, neurogenic inflammation, asthma,

micturition disorders such as urinary incontinence and nociception comprising administering to a human in need of such administration of an effective amount of a compound according to claim 1.

5


~~14.~~ 13. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound according to ~~any one of claims 1-9~~ claim 1.

10


~~15.~~ 14. (Currently Amended) A process for preparing a pharmaceutical composition ~~as claimed in claim 14,~~ characterized in that a pharmaceutically comprising  
mixing a pharmaceutically acceptable carrier is  
~~intimately mixed~~ with a therapeutically effective amount of a compound ~~as claimed in any one of claims 1-9~~ Claim 1.

15

20 ~~16.~~ 15. (Currently Amended) A process for the preparation of a compound of Formula (I'') in which an intermediate compound of Formula (II) is reacted with an intermediate compound of Formula (III), wherein the radicals  $R^2$ , X, Q,  $R^1$ , m, n, p and q are as defined in  
 25 claim 1.









17. 16. (Currently Amended) A process for the preparation of a compound of Formula (I') in which a final compound of Formula (I'') is reductively hydrogenated, wherein the radicals  $R^2$ , X, Q,  $R^1$ , m, n, p and q are as defined in claim 1.





18. 17. (Currently Amended) A process for the preparation of a compound according to Formula (I') comprising the consecutive steps of
- 1) obtaining a compound of Formula (I'') according to claim ~~16~~ 15;
  - 2) obtaining a compound of Formula (I') according to claim ~~17~~ 16.
18. (New) A compound select from the group consisting of

	2R-trans
	2R-trans

	2R-trans
	2R-trans
	2R-trans
	2R-trans
	2R-trans
	2R-trans



	2R-trans
and	
	2R-trans